Prevalencia de enfermedad de Fabry en pacientes en lista de trasplante y posttrasplante renal en fundación cardioinfantil Bogotá
| Contribuinte(s) |
Molano, Alejandra Wancjer, Benjamin Benavides, Carlos |
|---|---|
| Data(s) |
23/07/2015
|
| Resumo |
Introducción: La Enfermedad de Fabry (EF), es una enfermedad multisistémica de almacenamiento lisosomal ligada al cromosoma X que afecta principalmente a hombres, pero también puede causar significativa morbilidad en las mujeres heterocigotas (1–5). La deficiencia de la enzyma α-galactosidaseA (α-Gal A,) provoca acumulación de glicosfingolipidos que afectan diferentes tipos celulares entre ellos el endotelio vascular en vasos de pequeño calibre, células epiteliales y Músculo liso en el sistema cardiovascular (cardiomiocitos), sistema nervioso y células epiteliales tubulares del riñón (6,7). Complicaciones como la falla renal es la causa de muerte más frecuente en la EF (7,8). La incidencia se ha calculado en 1 de cada 117.000 nacidos vivos. (9). Objetivos: Determinar la prevalencia de la Enfermedad de Fabry en pacientes con Insuficiencia renal terminal que se encuentren en lista de trasplante y Post-trasplante Renal en Fundación Cardioinfantil Bogotá. Materiales y Métodos: Se realizó un estudio observacional en donde se evaluó la prevalencia de la EF en todos los sujetos mayores de 18 años que se encuentren en lista de trasplante y post-trasplante renal. Resultados: La prevalencia de Enfermedad de Fabry en 98 pacientes con enfermedad renal crónica fue de 7.1% para la muestra general y 12.9% para la muestra con etiología idiopática Conclusiones: La Enfermedad de Fabry es una importante casusa de Enfermedad Renal Crónica Terminal principalmente en el grupo de etiología idiopática. Palabras Clave: Enfermedad de Fabry (FA) Introduction: Fabry disease (EF) is a multisystemic lysosomal storage disease linked to the X chromosome which mainly affects men, but can also cause significant morbidity in heterozygous females (1-5). The deficiency of α-galactosidaseA Enzyma (α-Gal A) causes accumulation of glycosphingolipids that affect various cell types including vascular endothelium in small vessels, epithelial cells and smooth muscle in the cardiovascular system (cardiomyocytes), nervous system and kidney tubular epithelial cells (6,7). Complications 8 such as kidney failure is the most common cause of the EF (7.8) death. The incidence is estimated at 1 in 117,000 live births. (9). Objective: To determine the prevalence of Fabry disease in patients with end-stage renal failure who are on the transplant list and after renal transplantation in Bogota Cardioinfantil Foundation. Materials and Methods: An observational study in which the prevalence of FD in all subjects older than 18 who are on the transplant list and post-renal transplant was performed was evaluated. Results: According to this population screening in all 98 patients was 7.1% positive subjects Conclusions: Fabry disease is an important casus Terminal Chronic Renal Disease mainly in the group of idiopathic etiology. Keywords: Fabry disease (FD) |
| Formato |
application/pdf |
| Identificador | |
| Idioma(s) |
spa |
| Publicador |
Facultad de Medicina |
| Direitos |
info:eu-repo/semantics/openAccess |
| Fonte |
instname:Universidad del Rosario reponame:Repositorio Institucional EdocUR Desnick RJ, Brady R, Barranger J, Collins AJ, Germain DP, Goldman M, et al. Fabry disease, an under-recognized multisystemic disorder: Expert recommendations for diagnosis, management, and enzyme replacement therapy. Annals of Internal Medicine. 2003. p. 338–46. Ioannou YA, Zeidner KM, Gordon RE, Desnick RJ. Fabry disease: preclinical studies demonstrate the effectiveness of alpha-galactosidase A replacement in enzyme-deficient mice. Am J Hum Genet. 2001;68(1):14–25 Bishop DF, Kornreich R, Desnick RJ. Structural organization of the human alpha-galactosidase A gene: further evidence for the absence of a 3’ untranslated region. Proc Natl Acad Sci U S A. 1988;85(11):3903–7. Redonnet-Vernhet I, Ploos van Amstel JK, Jansen RP, Wevers RA, Salvayre R, Levade T. Uneven X inactivation in a female monozygotic twin pair with Fabry disease and discordant expression of a novel mutation in the alpha-galactosidase A gene. Journal of medical genetics. 1996. p. 682–8. Hasholt L, Sørensen SA, Wandall A, Andersen EB, Arlien-Søborg P. A Fabry’s disease heterozygote with a new mutation: biochemical, ultrastructural, and clinical investigations. Journal of medical genetics. 1990. p. 303–6. Pabico RC, Atancio BC, McKenna BA, Pamukcoglu T, Yodaiken R. Renal pathologic lesions and functional alterations in a man with Fabry’s disease. Am J Med. 1973;55(3):415–25. Desnick RJ, Blieden LC, Sharp HL, Hofschire PJ, Moller JH. Cardiac valvular anomalies in Fabry disease. Clinical, morphologic, and biochemical studies. Circulation. 1976. p. 818–25. Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA. 1999;281(3):249–54. Siamopoulos KC. Fabry disease: Kidney involvement and enzyme replacement therapy. Kidney International. 2004. p. 744–53. Brady RO, Gal AE, Bradley RM, Martensson E, Warshaw AL, Laster L. Enzymatic defect in Fabry’s disease. Ceramidetrihexosidase deficiency. The New England journal of medicine. 1967. Kornreich R, Desnick RJ, Bishop DF. Nucleotide sequence of the human alpha-galactosidase A gene. Nucleic Acids Res. 1989;17(8):3301–2. Krawczak M, Ball E V, Fenton I, Stenson PD, Abeysinghe S, Thomas N, et al. Human gene mutation database-a biomedical information and research resource. Hum Mutat. 2000;15(1):45–51. Dawson G, Sweeley CC. In vivo studies on glycosphingolipid metabolism in porcine blood. J Biol Chem. 1970;245(2):410–6. Dawson G, Sweeley CC. In vivo studies on glycosphingolipid metabolism in porcine blood. J Biol Chem. 1970;245(2):410–6. Menkes DL. Images in neurology. The cutaneous stigmata of Fabry disease: an X-linked phakomatosis associated with central and peripheral nervous system dysfunction. Archives of neurology. 1999. p. 487. Morgan SH, Rudge P, Smith SJ, Bronstein AM, Kendall BE, Holly E, et al. The neurological complications of Anderson-Fabry disease (alpha-galactosidase A deficiency)--investigation of symptomatic and presymptomatic patients. Q J Med. 1990;75(277):491–507. Menkes DL, O’Neil TJ, Saenz KK. Fabry’s disease presenting as syncope, angiokeratomas, and spoke-like cataracts in a young man: discussion of the differential diagnosis. Military medicine. 1997. p. 773–6. Onishi A, Dyck PJ. Loss of small peripheral sensory neurons in Fabry disease. Histologic and morphometric evaluation of cutaneous nerves, spinal ganglia, and posterior columns. Arch Neurol. 1974;31(2):120–7. Cable WJ, Kolodny EH, Adams RD. Fabry disease: impaired autonomic function. Neurology. 1982;32(5):498–502. Sher NA, Letson RD, Desnick RJ. The ocular manifestations in Fabry’s disease. Arch Ophthalmol. 1979;97(4):671–6. Sheth KJ, Werlin SL, Freeman ME, Hodach AE. Gastrointestinal structure and function in Fabry’s disease. Am J Gastroenterol. 1981;76(3):246–51. Kampmann C, Baehner F, Ries M, Beck M. Cardiac involvement in Anderson-Fabry disease. J Am Soc Nephrol. 2002;13 Suppl 2:S147–9. Linhart A, Palecek T, Bultas J, Ferguson JJ, Hrudová J, Karetová D, et al. New insights in cardiac structural changes in patients with Fabry’s disease. Am Heart J. 2000;139(6):1101–8. Sachdev B, Takenaka T, Teraguchi H, Tei C, Lee P, McKenna WJ, et al. Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy. Circulation. 2002;105(12):1407–11. Mehta J, Tuna N, Moller JH, Desnick RJ. Electrocardiographic and vectorcardiographic abnormalities in Fabry’s disease. Am Heart J. 1977;93(6):699–705. Goldman ME, Cantor R, Schwartz MF, Baker M, Desnick RJ. Echocardiographic abnormalities and disease severity in Fabry’s disease. J Am Coll Cardiol. 1986;7(5):1157–61. Nagao Y, Nakashima H, Fukuhara Y, Shimmoto M, Oshima A, Ikari Y, et al. Hypertrophic cardiomyopathy in late-onset variant of Fabry disease with high residual activity of alpha-galactosidase A. Clinical genetics. 1991. p. 233–7. Mitsias P, Levine SR. Cerebrovascular complications of Fabry’s disease. Ann Neurol. 1996;40(1):8–17. Mendez MF, Stanley TM, Medel NM, Li Z, Tedesco DT. The vascular dementia of Fabry’s disease. Dementia and geriatric cognitive disorders. p. 252–7. Nakao S, Kodama C, Takenaka T, Tanaka A, Yasumoto Y, Yoshida A, et al. Fabry disease: Detection of undiagnosed hemodialysis patients and identification of a “renal variant” phenotype. Kidney Int. 2003;64(3):801–7. Largent EA, Pearson SD. Which orphans will find a home? The rule of rescue in resource allocation for rare diseases. Hastings Cent Rep. 2012;42(1):27–34. Jonsen AR. Bentham in a box: technology assessment and health care allocation. Law Med Health Care. 1986;14(3-4):172–4. Waldek S, Feriozzi S. Fabry nephropathy: a review - how can we optimize the management of Fabry nephropathy? BMC Nephrol [Internet]. 2014;15(1):72. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4029839&tool=pmcentrez&rendertype=abstract Romão EA, Lourenço CM, Júnior WM, Rolfs A, Muñoz V, Neto OMV, et al. What lies beneath: Fabry nephropathy in a female patient with severe cerebrovascular disease. Clinical Nephrology. 2012. Eng CM, Fletcher J, Wilcox WR, Waldek S, Scott CR, Sillence DO, et al. Fabry disease: Baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry. J Inherit Metab Dis. 2007;30(2):184–92. Ardila Cardenas Maria Elizabeth MS. Prevalencia de la enfermedad de Fabry en hombres con Insuficiencia Renal Cronica en Unidades Renales de RTS Colombia. Cat Univ del Rosario. 2008; Kalkan Uçar S, Sozmen E, Duman S, Başçi A, Çoker M. Alpha-Galactosidase A Activity Levels in Turkish Male Hemodialysis Patients. Ther Apher Dial. 2012;16(6):560–5. Terryn W, Cochat P, Froissart R, Ortiz A, Pirson Y, Poppe B, et al. Fabry nephropathy: Indications for screening and guidance for diagnosis and treatment by the European Renal Best Practice. Nephrology Dialysis Transplantation. 2013. p. 505–17. “Rare Diseases: understanding this Public Health Priority” [Internet]. Understanding this Public Health Priority - Eurordis. 2005. Available from: www.eurordis.org/IMG/.../princeps_document-EN.p... Goolsby MJ. National Kidney Foundation Guidelines for chronic kidney disease: evaluation, classification, and stratification. J Am Acad Nurse Pract. 2002;14(6):238–42. Miners AH, Holmes A, Sherr L, Jenkinson C, MacDermot KD. Assessment of health-related quality-of-life in males with Anderson Fabry Disease before therapeutic intervention. Qual Life Res. 2002;11(2):127–33. Hwu WL, Chien YH, Lee NC, Chiang SC, Dobrovolny R, Huang AC, et al. Newborn screening for fabry disease in taiwan reveals a high incidence of the later-onset GLA mutation c.936+919G>A (IVS4+919G>A). Hum Mutat. 2009;30(10):1397–405. Maixnerová D, Tesař V, Ryšavá R, Reiterová J, Poupětová H, Dvořáková L, et al. The coincidence of IgA nephropathy and Fabry disease. BMC Nephrol [Internet]. 2013;14:6. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3549770&tool=pmcentrez&rendertype=abstract |
| Palavras-Chave | #Enfermedad de Fabry #616.043 #Medicina Interna #Genética #Enfermedades Cardiovasculares #Enfermedades del Sistema Nervioso #Enfermedades Genéticas Congénitas #Fabry disease (FD) |
| Tipo |
info:eu-repo/semantics/bachelorThesis info:eu-repo/semantics/acceptedVersion |
